EUVIMEDEUVIMED entdecken
Crossref

Normal SFLC Ratio in Newly Diagnosed Myeloma: A Potential Biomarker of Non‐High‐Risk and Nonaggressive Disease

Manish K Singh iD, Yadav Sanjeev, Akshita Pandey, Khaliqur Rahman iD, Mona Vijayran iD, Poorvi Kapoor, Sayan Sinha Roy, Ruchi Gupta, Dinesh Chandra, Kaushal Kumar, Vineet Sharma, Rajesh Kashyap iD

International Journal of Laboratory Hematology · 2026

DOI: 10.1111/ijlh.70058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2026. Verfasst von Manish K Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoglobulin Light Chains, Biomarkers, Tumor. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Research Cell, SGPGIMS, Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The myeloma patients with baseline normal/near‐normal serum free light chain (SFLC) ratio have been reported to respond favorably to the treatment, unlike patients with extreme/abnormal SFLC ratio. We hypothesized that this normal SFLC ratio could serve as a biomarker for favorable cytogenetic and outcome profiles. Materials and Methods The flow cytometric immunophenotyping (FCM‐IPT) and interphase FISH analysis of marrow aspirate were performed as per recommended guidelines, in all the newly diagnosed patients of plasma cell proliferative disorders, enrolled during this prospective study. Patients were risk‐stratified as per ISS, R‐ISS, and R2‐ISS criteria. The outcome evaluation, in patients treated with standard 3‐/4‐drugs induction, was done at least 3 months after initiation of therapy.

Results

A total of 306 patients with plasma cell proliferative disorders were enrolled; myeloma patients were 240 ( n_SFLC = 23/240, 9.6%) and ( ab_SFLC = 217/240, 90.4%). IgG lambda M‐protein was more significantly seen in ( n_SFLC ) patients. None of the patients in the ( n_SFLC ) group showed circulating blood plasma cells. The ( n_SFLC ) patients did not show the presence of TP53 gene deletion and relatively lacked other high‐risk genetics. The outcome analysis showed that more patients in the ( n_SFLC ) group attained ≥ VGPR (88.9% vs. 65.4% of ab_SFLC ).

Conclusion

Based on this, we infer that the patients with a normal SFLC ratio are enriched with non‐high‐risk features and behave less aggressively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunoglobulin Light ChainsBiomarkers, TumorHumansFemaleMaleImmunophenotypingMiddle AgedAgedProspective StudiesFlow CytometryAdultPrognosis

Stichwörter der Autor:innen

VGPRdouble‐hit myelomamyelomanormal SFLC ratiotriple‐hit myeloma

Substanzen

Immunoglobulin Light ChainsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

ORCID-Profile: Manish K Singh, Khaliqur Rahman, Mona Vijayran, Rajesh Kashyap

Förderung

  • Research Cell, SGPGIMS
  • Indian Council of Medical Research

Zitieren

APA

Singh, M. K., Sanjeev, Y., Pandey, A., Rahman, K., Vijayran, M., Kapoor, P., Roy, S. S., Gupta, R., Chandra, D., Kumar, K., Sharma, V., & Kashyap, R. (2026). Normal SFLC Ratio in Newly Diagnosed Myeloma: A Potential Biomarker of Non‐High‐Risk and Nonaggressive Disease. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.70058

Vancouver

Singh MK, Sanjeev Y, Pandey A, Rahman K, Vijayran M, Kapoor P, et al. Normal SFLC Ratio in Newly Diagnosed Myeloma: A Potential Biomarker of Non‐High‐Risk and Nonaggressive Disease. International Journal of Laboratory Hematology. 2026. doi:10.1111/ijlh.70058

BibTeX
@article{Singh2026,
  author = {Singh, Manish K and Sanjeev, Yadav and Pandey, Akshita and Rahman, Khaliqur and Vijayran, Mona and Kapoor, Poorvi and Roy, Sayan Sinha and Gupta, Ruchi and Chandra, Dinesh and Kumar, Kaushal and Sharma, Vineet and Kashyap, Rajesh},
  title = {Normal SFLC Ratio in Newly Diagnosed Myeloma: A Potential Biomarker of Non‐High‐Risk and Nonaggressive Disease},
  journal = {International Journal of Laboratory Hematology},
  year = {2026},
  doi = {10.1111/ijlh.70058}
}
Kostenlos starten →